|Cancer Stem Cell News 6.27 July 12, 2017|
Scientists showed that brain tumor-initiating cell (BTIC) growth arrest in vitro and in vivo is accomplished via concurrent siRNA knockdown of four transcription factors that drive the proneural BTIC phenotype delivered by multiplexed siRNA encapsulation in the lipopolymeric nanoparticle 7C1. [Proc Natl Acad Sci USA]
Researchers investigated the mechanisms by which progesterone receptors (PR) and retinoic acid receptors regulate CK5 expression and breast CSC activity. After P4 treatment, sorted CK5+ compared to CK5− cells were more tumorigenic in vivo. In vitro, P4-treated breast cancer cells formed larger mammospheres and silenced CK5 using a small hairpin RNA abolished by this P4-dependent increase in mammosphere size. [Oncogene]
Traditional therapies usually kill the bulk of cancer cells, but are often unable to effectively eliminate CSCs, which may lead to drug resistance and cancer relapse. Investigators proposed a novel strategy fabricating multifunctional magnetic Fe3O4@PPr@HA hybrid nanoparticles and loading it with the Notch signaling pathway inhibitor N-[N-(3,5-difluorophenacetyl-l-alanyl)]-S-phenylglycinet-butylester to eliminate CSCs. [ACS Appl Mater Interfaces]
Researchers showed that retinol binding protein 4 (RBP4) and STRA6 expression is associated with poor oncologic prognosis. They showed that high-fat diet increased LGR5 expression and promotes tumor growth in a xenograft model independent of obesity. [Stem Cell Reports]
Cervical cancer stem-like cells (CaCxSLCs) isolated and enriched from cervical cancer cell lines SiHa and C33a demonstrated an elevated AP-1 DNA-binding activity in comparison to non-stem cervical cancer cells. Upon UV-irradiation, CaCxSLCs showed a UV exposure duration-dependent higher proliferation and highly increased AP-1 activity whereas it was completely abolished in non-stem cancer cells. [Sci Rep]
The authors investigated the location of CD133 expression in hepatocellular carcinoma (HCC) and this location’s potential value as a prognostic indicator of survival in patients with HCC. The results showed that the CD133 protein expression levels of HCC in both the cytoplasm and nucleus were significantly higher than adjacent normal liver tissue. [BMC Cancer]
Investigators examined the impact of extracellular matrix proteins on pancreatic ductal adenocarcinoma (PDAC) CSCs. Type I collagen increased PDAC tumor initiating potential, self-renewal, and the frequency of CSCs through the activation of FAK. [PLoS One]
Scientists synthesized and investigated the potential of a new Indole-3-carbaldehyde derivative (NI-3-CD) in inhibiting the expression of self-renewal regulatory factors and cancer stem cell gene in a leukemia cell line NB4. There was a significant difference in cell viability, when various concentrations of NI-3- were used for 24, 48 and 72 hours in comparison to I3C regarding the cellular viability. [Immunol Lett]
Salinomycin, which has been reported to kill CSCs, was used in combination with docetaxel, a chemotherapeutic drug that is used as first-line therapy in gastric cancer (GC), to eradicate both GC stem cells (SCs) and cancer cells. The authors found that both salinomycin and salinomycin-loaded nanoparticles could selectively eradicate GC SCs whereas docetaxel and docetaxel-loaded nanoparticles could significantly eradicate GC cells. [Anticancer Drugs]
Researchers summarize the most recent studies assessing the role of redox homeostasis, autophagy and chemoresistance in cancer stem cells, including some novel findings on micro-RNAs and their role in horizontal transfer within cancer cell populations. [Antioxid Redox Signal]
The authors review the recent evidence for intestinal stem cells and colon cancer stem cells, methods to detect the tumor-initiating cells, and clinical significance of cancer stem cell markers. They describe the emerging problems of cancer stem cell theory, including bidirectional conversion and intertumoral heterogeneity of stem cell phenotype. [Int J Mol Sci]
Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.
Regen BioPharma Inc. reported continued progress in developing small molecule drugs that activate and inhibit NR2F6. The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor and cancer stem cell differentiator. [Regen BioPharma Inc. (PR Newswire Association LLC.)]
Boston Biomedical, Inc. announced the U.S. FDA has granted Orphan Drug Designation or DSP-7888, an investigational cancer peptide vaccine, for the treatment of myelodysplastic syndrome. [Boston Biomedical, Inc.]
The Food and Drug Administration has changed its tune on an experimental drug for a deadly rare disease, withdrawing a request that the company developing it run another clinical trial. The unusual move comes after President Trump met with the company’s CEO — and promised to speed up what he called a “slow and burdensome” process for drug approvals. [STAT news]
US President Donald Trump has pledged to shrink the federal government, and he seems to be starting with science. Nearly six months after taking office, Trump has not chosen a science adviser, and the White House’s Office of Science and Technology Policy has dwindled from around 130 staff members under former president Barack Obama to 35. [Nature News]
Obstetrician and gynecologist Brenda Fitzgerald will direct the US Centers for Disease Control and Prevention, Secretary of Health and Human Services Tom Price announced. [Nature News]
In an unprecedented court case in Paris, an eminent French lung specialist has been fined €50,000 and given a six-month suspended jail sentence because he didn’t disclose his ties to the oil industry during a Senate air-pollution inquiry. [Nature News]
NEW 2017 National Cancer Research Institute (NCRI) Cancer Conference
Visit our events page to see a complete list of events in the community.
Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!
Comments or suggestions? Submit your feedback here.
Home Cancer Stem Cell News Volume 6.27 | Jul 12 2017